Vanguard Group Inc. Sells 107,651 Shares of Medpace Holdings, Inc. $MEDP

Vanguard Group Inc. trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,282,972 shares of the company’s stock after selling 107,651 shares during the period. Vanguard Group Inc. owned approximately 8.10% of Medpace worth $1,173,813,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Clarkston Capital Partners LLC bought a new position in Medpace during the second quarter valued at approximately $40,569,000. Cibc World Market Inc. purchased a new stake in Medpace during the 3rd quarter valued at $5,033,000. Brighton Jones LLC lifted its holdings in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after buying an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Medpace by 150.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after buying an additional 9,117 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its stake in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.6%

NASDAQ MEDP opened at $453.77 on Friday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The company has a market capitalization of $12.88 billion, a P/E ratio of 29.66, a price-to-earnings-growth ratio of 2.17 and a beta of 1.42. The stock’s 50-day moving average price is $556.01 and its 200-day moving average price is $538.67.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same period in the previous year, the company posted $3.67 EPS. The firm’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insiders Place Their Bets

In related news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO August J. Troendle sold 59,025 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 201,745 shares of company stock worth $122,369,738. 20.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on MEDP. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research report on Tuesday, February 10th. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Mizuho set a $582.00 price objective on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their price objective for the stock from $462.00 to $419.00 in a report on Wednesday. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $483.45.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.